Clinical trials: Hypersensitivity Reactions
Hypersensitivity Reactions
Post-market Safety Study of LUMISIGHT
This study is a prospective, multi-center, observational post-market safety study evaluating the incidence of anaphylaxis and hypersensitivity reactions associated with LUMISIGHT (pegulicianine) administration in adults with…
- Trial name
- NCT07572162
- Where
- 2 sites in United States
- Volunteers
- 1,500 people
- Sponsor
- Lumicell, Inc.
Allergic Reaction (IgA) Vasculitis
Evaluate the Effectiveness and Safety of BBD-1 Multi-target Immune Enhancement Targeting Agent in the Treatment of Hypersensitivity Reaction (IgA) Vasculitis
Hypersensitivity (IgA) vasculitis is a common vascular allergic disease, the cause of which is not yet clear, and may involve infection, immune disorders, heredity and other factors. It belongs to the category of immune diseases.
- Trial name
- NCT07595367
- Testing
- BBD-1 Multi target Immune Enhancement Targeting Agent
- Where
- 2 sites in United States, China
- Volunteers
- 30 people
- Sponsor
- Qifeng Zhang
Allergic Reaction
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of DESF in Pediatric Subjects
An open-label study to assess the pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of epinephrine administered as a single dose of DESF in pediatric subjects weighing ≥30 kg with a personal history of…
- Trial name
- PARKS (NCT07703982)
- Testing
- DESF
- Where
- 8 sites in United States, Canada
- Volunteers
- 32 people
- Sponsor
- Aquestive Therapeutics
Allergic Reactions
Study Evaluating the Safety and Efficacy of Neffy or Intramuscular Adrenalin in Patients With Allergic Reactions After Oral Food Challenge or Allergen Immunotherapy
The study is to assess the safety of neffy or IM Adrenalin in patients who are experiencing allergic reactions after an OFC, allergen Immunotherapy (AIT), or other allergy challenge that may require epinephrine intervention.
- Trial name
- NCT06834165
- Testing
- Neffy, Adrenaline
- Where
- 6 sites in United States
- Volunteers
- 600 people
- Sponsor
- ARS Pharmaceuticals, Inc.
Allergy Pollen, Allergic Reaction
Phleum Pratense and Dactylis Glomerata Allergen Extracts Standardization
The primary objective is to assess the concentration of each allergen extract (Phleum pratense and Dactylis glomerata) that induces a wheal size equivalent to that produced by a 10 mg/mL histamine dihydrochloride solution.
- Conditions
- Allergy Pollen, Allergic Reaction, Allergic Skin Reaction
- Trial name
- NCT06957496
- Testing
- Allergenic extracts
- Where
- Spain
- Volunteers
- 31 people
- Sponsor
- Inmunotek S.L.
Allergic Reactions, Allergic Skin Reaction
Determination of Blomia Tropicalis Allergen Extract in Prick Test Units
The primary objective is to assess the concentration of Blomia tropicalis allergenic extract that induces a wheal of size equivalent to that produced by a 10 mg/mL histamine dihydrochloride solution, in order to be used as…
- Trial name
- NCT07195929
- Testing
- Allergenic Extract
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Inmunotek S.L.
Allergic Reaction
Pharmacokinetics Study of DESF in Adults With Oral Allergy Syndrome
A 2-part open-label study to assess the pharmacokinetics (PK) and pharmacodynamics (PD) of epinephrine administered as single and repeat doses of DESF in healthy adults with oral allergy syndrome (OAS).
- Trial name
- OASIS (NCT06527937)
- Testing
- DESF, Epinephrine Injection
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Aquestive Therapeutics
Allergic Reaction, Allergic Skin Reaction
Quercus Ilex and Quercus Robur Allergen Extracts Standardisation
The objective of this study is to determine the biological activity of Quercus illex and Quercus robur allergen extracts in histamine equivalent prick (HEP) units, in order to be used as in-house reference preparation (IHRP).
- Conditions
- Allergic Reaction, Allergic Skin Reaction, Allergy Pollen
- Trial name
- NCT05532566
- Testing
- Allergenic extract
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Inmunotek S.L.
Detection of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 in Individuals Exposed to SARS-CoV-2
Assessment of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 Peptide Antigens
This dose finding, multi-cohort study is designed to evaluate the safety and efficacy of intradermally-injectedTNX-2100, synthesized SARS-CoV-2 peptide antigens and assess the presence and magnitude of DTH reactions.
- Trial name
- COVID-19 DTH (NCT05216510)
- Testing
- TNX-2110, TNX-2120, TNX-2130
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Tonix Pharmaceuticals, Inc.
Allergy Pollen, Allergic Reaction
Juniperus Oxycedrus and Cupressus Arizonica Allergen Extracts Standardisation.
The objective of this study is to determine the biological activity of Juniperus oxycedrus and Cupressus arizonica. allergen extracts in histamine equivalent prick (HEP) units, in order to be used as in-house reference…
- Conditions
- Allergy Pollen, Allergic Reaction, Allergic Skin Reaction
- Trial name
- NCT05533385
- Testing
- Allergenic extract
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Inmunotek S.L.
Allergic Reactions
Study Evaluating Chlorpheniramine Maleate Liquid in Children and Adolescents
The purpose of this study is to examine the pharmacokinetic parameters of chlorpheniramine in children and adolescents.
- Trial name
- NCT00837837
- Testing
- Chlorpheniramine
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Allergic Reactions
Study Evaluating Brompheniramine Maleate Liquid in Children and Adolescents
The objective of this study is to characterize the pharmacokinetic (PK) profile of brompheniramine maleate (BROM) in children and adolescents, ages 2 to less than 18 years following dosing in accordance with current weight-age…
- Trial name
- NCT00894634
- Testing
- Brompheniramine maleate
- Volunteers
- 37 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Allergic Reaction
Allergy Potential of Omeza Collagen Matrix in Human Subjects Using the Skin Prick Method
Single-center, monadic, one day study utilizing the skin prick method to assess the allergy potential of Omeza Collagen Matrix in Human Subjects
- Trial name
- NCT04510376
- Testing
- Test Article, Positive Control, Negative Control
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Omeza, LLC
Arhythmia, Atrioventricular Heart-block
Observation of ImageReady™ MR Conditional Pacing System in China
To observe the safety and efficacy of ImageReady™ MR Conditional Pacing System in Chinese subjects
- Conditions
- Arhythmia, Atrioventricular Heart-block, Chronic Bundle Branch or Branch Block, Carotid Sinus Hypersensitivity Reaction Syndrome
- Trial name
- NCT02636712
- Testing
- ImageReady™ MR Conditional Pacing System
- Where
- 2 sites in China
- Volunteers
- 10 people
- Sponsor
- Boston Scientific Corporation
Allergic Skin Reaction
Evaluation of the Allergenicity of AMPHADASE INJECTION (Hyaluronidase Injection USP)
This study is designed to evaluate the allergenicity of Amphadase® in healthy volunteers using an intradermal skin test.
- Trial name
- H001-A2 (NCT01689363)
- Testing
- Hyaluronidase, Histamine, Saline
- Where
- 5 sites in United States
- Volunteers
- 253 people, healthy volunteers welcome
- Sponsor
- Amphastar Pharmaceuticals, Inc.
Allergic Reactions
Study of Valortim® (MDX-1303) and Its Selected Formulation Components Percutaneous Use
The purpose of this study is to determine if Valortim, or one or more of its selected formulation components, induces a wheal reaction when introduced percutaneously.
- Trial name
- NCT01204866
- Testing
- Valortim and selected Components
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- PharmAthene, Inc.
Hemophilia B, Allergic Reactions
Study to Describe the Allergic Reactions to Factor IX in Patients With Hemophilia B
Retrospective, multicenter study in patients with hemophilia B. This study will be placed at 20 to 50 hemophilia treatment centers in North America and the EU, and is designed to estimate the frequency of Class II and III…
- Trial name
- NCT00195221
- Where
- 38 sites in United States, Austria and 7 more
- Volunteers
- 166 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer